Skip to content

The Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery

A Cluster Randomized Trial on the Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery (Re-Team)

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06684080
Acronym
RE-TEAM
Enrollment
52000
Registered
2024-11-12
Start date
2025-01-01
Completion date
2027-06-30
Last updated
2025-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Delivery

Keywords

Postpartum Hemorrhage, cesarean delivery, Randomized trial, Detection, treatment

Brief summary

Delays in the detection or inconsistent use of effective interventions of postpartum hemorrhage can result in complications or death. We designed a cluster-randomized trial to assess a multi-component strategy for the detection and treatment of postpartum hemorrhage after cesarean delivery.

Interventions

OTHERA care bundle

1. Risk evaluation for PPH and Reserve plan; 2. Assess blood loss using Estimated Blood Loss Form and amnion fluid collection drape; 3. Satisfy any of the following conditions: i. If the estimated blood loss reaches 500ml but is less than 1000ml, and any of the following abnormal indicators are present; ii. If the estimated blood loss reaches 1000ml, no other indicators need to be considered: 1) Lack of uterine contractions 2) Persistent bleeding 3)Shock index (heart rate/systolic blood pressure) was greater than 0.9 Initiate the following protocols①, ②, ③, ④ * Maintain uterus tone (Administration of Oxytocin and second-line medications to promote uterine contraction) * Intravenous infusion ③ Administered tranexamic acid ④ Multi-methods and Multi-disciplinary

Sponsors

Dunjin Chen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Hospital level 1. Public hospitals 2. There are more than 100 cesarean deliveries per year * Patient level 1. Cesarean delivery 2. Sign informed consent

Exclusion criteria

* Hospital level 1\. Data verification information cannot be provided * Pregnant woman level 1. No blood routine results within 2 weeks before surgery

Design outcomes

Primary

MeasureTime frameDescription
Incidence of PPHDay 2defined by a calculated estimated blood loss \> 1000 mL \[Calculated estimated blood loss = estimated blood volume × (preoperative hematocrit - postoperative hematocrit)/preoperative hematocrit (where estimated blood volume (mL) = weight (Kg) × 85)\] or red blood cell (RBC) transfusion before day 2 postpartum .

Secondary

MeasureTime frameDescription
Estimated blood losspostpartum 24 hoursEstimated intraoperative and postoperative blood loss at 24 hours
Incidence of postpartum transfusionbaselineinfusion of RBC, plasma, platelet, or cryo et al
Incidence of additional operations performed outside cesarean sectionbaselineAdditional operations include B-Lnych, uterine artery suture, partial hysterectomy, hysterectomy et al
mean total calculated blood lossDay 2Calculated estimated blood loss = estimated blood volume × (preoperative hematocrit - postoperative hematocrit)/preoperative hematocrit (where estimated blood volume (mL) = weight (Kg) × 85)\]
Incidence of maternal death from any causeUp to 42 daysmaternal death from any cause
The adherence to the treatment bundleintraoperation and postpartum 24 hoursdefined adherence to at least four core bundle elements: risk evaluation for PPH and reserve plan, maintaining uterus tone (administration of oxytocin and second-line medications to promote uterine contraction), intravenous infusion, administered tranexamic acid
Incidence of transfer to intensive care unitbaselinetransfer to intensive care unit

Contacts

Primary ContactLizi M.D.
2022390064@gzhmu.edu.cn086-13265352553

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026